Angelini Ventures has co-led a €105 million Series A financing round for French biopharmaceutical company Adcytherix, focusing on innovative antibody-drug conjugates for cancer treatment.

Target Company Overview

Adcytherix is a cutting-edge biopharmaceutical company based in France, specializing in the development of innovative antibody-drug conjugates (ADCs). The company is dedicated to addressing significant unmet medical needs in cancer treatment through its pioneering research and development efforts. Adcytherix seeks to leverage advanced technologies to create therapeutic solutions that improve patient outcomes.

In 2025, Adcytherix has successfully secured €105 million in a Series A financing round, marking the largest Series A in the ADC sector in Europe. This substantial investment will enable the company to advance its lead therapeutic candidate, ADCX-020, into clinical trials, with anticipated regulatory submissions targeted for the end of 2025. Additionally, the fund will support the expansion of Adcytherix's proprietary ADC pipeline, utilizing cutting-edge payload technologies to counteract treatment resistance in various cancer types.

Industry Overview in France

The biotechnology industry in France is a robust and rapidly growing sector, characterized by significant innovation and investment. France boasts a rich ecosystem of research institutions, universities, and collaborative networks that